80 likes | 88 Views
Altogen Biosystems offers the BT 20 Cell Transfection Reagent, a lipid-mediated formulation designed to provide high transfection efficiency in BT 20 breast carcinoma cells. This reagent is ideal for studying a range of biomedical therapeutics and biology, including breast cancer research and drug discovery. Visit www.Altogen.com to purchase the BT 20 Transfection Kit.
E N D
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products >BT-20 Transfection Reagent (Breast Carcinoma Cells) Altogen Biosystems offers the BT-20 Cell Transfection Reagent among a host of 100+ cell line specific In Vitro Transfection Kits. The BT-20 Cell Transfection Reagent is a lipid-mediated formulation, and it has been developed to provide high transfection efficiency with BT-20. This cell line is an excellent host for studying a range of areas within the field of biomedical therapeutics and biology as well as breast cancer in particular. When cultured in vitro, BT-20 cells are a monolayer and adhere to the surface of the culture flask. Other applications include drug discovery, gene expression studies, molecular and cell biology research applications. Purchase BT-20 Transfection Kit at www.Altogen.com Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989-0841 email techserv@altogen.com
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products >BT-20 Transfection Reagent (Breast Carcinoma Cells) BT-20 Cell Line Description and Applications The BT-20 cell line originates from the culturing of cells taken from a human breast carcinoma tumor. The cell line was established in 1958 from a 74-year-old Caucasian female patient suffering from breast cancer by E.Y. Lasfargues and L. Ozzello. The BT-20 cell line does not have estrogen receptors, but the cell line does express estrogen receptor mRNA that has an exon 5 deletion. This cell line is particularly useful for research surrounding breast cancer, but it also has applications for a variety of topics in biomedical research. High Density BT-20 cellswww.atcc.org Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989-0841 email techserv@altogen.com
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products >BT-20 Transfection Reagent (Breast Carcinoma Cells) BT-20 Transfection Protocol 1. Plate 10,000 - 15,000 BT-20 cells per well in 0.5 ml of complete growth medium 12–24 hours prior to transfection 2. Wash with 1xPBS and add 0.5 ml of fresh growth medium 3. Prepare transfection complexes by mixing 40 µl of serum-free medium, 5.5 µl of transfection reagent, and • 750 ng DNA (or mRNA), or • 30 nM - 50 nM of siRNA (or microRNA) *Referred to a final volume including growth medium 4. Incubate transfection complexes at RT for 15 - 30 minutes 5. Optional: Add 2 µl of Complex Condenser. This reagent reduces the size of transfection complex, therefore increasing transfection efficiency; however, it may increase cell toxicity 6. Add prepared transfection complexes to 0.5 ml of complete growth medium with BT-20 cells (from step 2) 7. Incubate cells at 37ºC in a humidified CO2 incubator 8. Assay for phenotype or target gene expression 48 - 72 hours after transfection Optional: Transfection efficiency can be increased by addition of Transfection Enhancer reagent. Add 2 µl of Transfection Enhancer reagent 12-24 hours after transfection If the viability of BT-20 cells being transfected is affected at 16 - 24 hours post-transfection, the level of cytotoxicity can be decreased by changing the growth medium and eliminating redundant exposure of cells to transfectant Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989-0841 email techserv@altogen.com
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products >BT-20 Transfection Reagent (Breast Carcinoma Cells) General Lipoplex-mediated Transfection Mechanism of Action Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989-0841 email techserv@altogen.com
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products >BT-20 Transfection Reagent (Breast Carcinoma Cells) BT-20 Transfection Kit Product Details • Two-component formulation enhances lipid-mediated transfection efficiency • Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA • Kit includes Transfection Enhancer reagent and recommended transfection protocol • High transfection efficacy in the presence of serum • Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid • Reproducible transfection results • Works well for standard reverse transfection and high-throughput applications • Developed and manufactured by Altogen Biosystems (www.Altogen.com) Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989-0841 email techserv@altogen.com
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products >BT-20 Transfection Reagent (Breast Carcinoma Cells) Data Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into BT20 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products >BT-20 Transfection Reagent (Breast Carcinoma Cells) Data Figure 2. Protein expression of Lamin A/C in BT-20 cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into BT-20 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products >BT-20 Transfection Reagent (Breast Carcinoma Cells) BT-20 Transfection Kit Benefits • Pre-optimized transfection protocol for BT-20 cell line • Compatible with DNA, small RNA (siRNA, shRNA, miRNA), mRNA, and small protein complexing • Free of serum and protein of animal origin • Compatible with standard and reverse transfection methods (both protocols provided in the kit manual) • Easy to use BT-20 transfection protocol ensures great performance with expedited experimental timeline • Equally efficient for single or multiple transfections • Can be used for transient transfection and development of stable BT-20 cell lines • Bio-degradable after endocytosis • Used for preclinical research worldwide Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989-0841 email techserv@altogen.com